The president's proposed budget cuts to the NIH would eventually result in fewer drugs on the market, the U.S. Congressional ...

Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a ...

2025年7月3日，迪哲医药（股票代码：688192.SH）宣布，舒沃哲（ZEGFROVY，通用名：舒沃替尼片）的新药上市申请（New Drug ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that the U.S. Food and Drug Administration (FDA) accepted for review ...

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

A new report looks at hiring trends © 2025 American City Business Journals. All rights reserved. Use of and/or registration ...

Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug FilingKANSAS ...

The U.S. Congressional Budget Office (CBO) cautioned that President Trumps proposed 2026 federal budgetfeaturing deep cuts to ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.